XML 33 R13.htm IDEA: XBRL DOCUMENT
v3.26.1

Acquisition of BioStrand | 12 Months Ended
--- | ---
Apr. 30, 2026
Biostrand BV |
Disclosure Of Business Combinations [Line Items] |
ACQUISITION OF BIOSTRAND | 6. ACQUISITION OF BIOSTRAND On April 13, 2022, the Company acquired all the issued and outstanding shares of BioStrand BV, BioKey BV, BioClue BV and Idea Family SRL (collectively “BioStrand”) on terms as follows: €2.7 million (CAD $3.7 million) was paid in cash on closing; 4,077,774 common shares of the Company were issued on closing; Deferred cash payment of €0.5 million (CAD $0.7 million) to be paid 90 days subsequent to closing; and Deferred cash payment of €0.5 million (CAD $0.6 million) to be paid over 3 years on the anniversary of the closing date. BioStrand focuses on technology in the field of bioinformatics and biotechnology related to the identification of characteristic biological sequences in proteins, RNA and DNA, and their different information layers, the development of a knowledge base containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare processed biological sequences. The acquisition provides the Company with advanced omics capabilities to enhance its antibody discovery processes and offer multi-omics data analysis to its clients. The transaction was accounted for as a business combination, as the operations of BioStrand meet the definition of a business. As the transaction was accounted for as a business combination, legal and consulting costs of $0.7 million and $0.1 million, respectively, were expensed during the year ended April 30, 2022. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets will represent the sales growth potential and assembled workforce of BioStrand. During the three months ended July 31, 2022, the Company recorded the right-of-use assets and lease liabilities in connection with building and vehicle leases at BioStrand. During the three months ended October 31, 2022, the Company adjusted goodwill upon the finalization of the deferred cash payment paid 90 days subsequent to closing. Both adjustments occurred during the measurement period and were applied retrospectively. The Company has allocated the purchase price as follows:
(in thousands) |  | $ |
Cash |  |  | 4,985 |
Common shares of the Company |  |  | 29,126 |
Fair value of consideration |  |  | 34,111 |
Cash |  |  | 36 |
Amounts receivable |  |  | 80 |
Unbilled revenue |  |  | 8 |
Equipment and right-of-use assets |  |  | 247 |
Intellectual property (not deductible for tax purposes) |  |  | 28,459 |
Proprietary processes (not deductible for tax purposes) |  |  | 391 |
Goodwill (not deductible for tax purposes) |  |  | 12,658 |
Accounts payable and accrued liabilities assumed |  |  | (342 | )
Deferred revenue |  |  | 9 |
Leases |  |  | (223 | )
Deferred income tax liability |  |  | (7,212 | )
|  |  | 34,111 |
The intellectual property assets are primarily comprised of acquired technology assets that are expected to have a useful life of 15 years. The fair value of the 4,077,774 common shares issued ($29.1 million) was determined based on the Canadian dollar equivalent of the consideration required of €21.3 million pursuant to the share purchase agreement using the closing stock price at` the date of the acquisition. The common shares are subject to an escrow agreement and will be released to the vendors on the following schedule: 15% one year after closing, 20% two years after closing, and 65% three years after closing. The deferred cash payments of €1.0 million was fair valued on the date of acquisition using a discounted cash flow model. The changes in the value of the subsequent payments during the years ended April 30, 2026, 2025 and 2024 are as follows:
(in thousands) |  | $ |
Balance, April 30, 2024 |  |  | 285 |
Foreign exchange |  |  | 19 |
Accretion |  |  | 10 |
Balance, April 30, 2025 |  |  | 314 |
Foreign exchange |  |  | (2 | )
Deferred acquisition payments |  |  | (312 | )
Accretion |  |  | — |
Balance, April 30, 2026 |  |  | — |
The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments (see Note 18).

X
- Definition The entire disclosure for business combinations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2025-01-01 -Section Disclosures -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=hyft_BiostrandBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |